Considering the downregulation of Tpm1.6 and Tpm1.7 in squamous cell carcinoma of esophagus as a potent biomarker.

AIM Squamous cell carcinoma of esophagus (SCCE) is an aggressive disease with a poor prognosis. Tropomyosins attach to actin microfilaments, providing its stability. Nonmuscle cells express Tpm isoforms such as Tpm1.6 and Tpm1.7 which are involved in cytoskeleton functional properties regulation. MATERIALS & METHODS The expression of Tpm1.6 and Tpm1.7 was analyzed in SCCE tissues and its association with clinicopathological parameters and survival of patients was assessed. RESULTS Tpm1.6 and Tpm1.7, besides TPM1 mRNA decreased considerably in SCCE tissues relative to normal esophageal tissues (p < 0.001). TPM1 downregulation level was significantly associated with the degree of tumor differentiation (p = 0.017). CONCLUSION Tpm1.6 and Tpm1.7 suppression play a crucial role in esophagus tumorigenesis and could be associated with SCCE poor prognosis.

[1]  Maryam Zare,et al.  Aberrant miRNA promoter methylation and EMT‐involving miRNAs in breast cancer metastasis: Diagnosis and therapeutic implications , 2018, Journal of cellular physiology.

[2]  C. Abnet,et al.  Epidemiology of Esophageal Squamous Cell Carcinoma. , 2017, Gastroenterology.

[3]  M. Krasna,et al.  Overview of esophageal cancer. , 2017, Annals of cardiothoracic surgery.

[4]  Yiping Li,et al.  Tropomyosin-1 acts as a potential tumor suppressor in human oral squamous cell carcinoma , 2017, PloS one.

[5]  Shaobin Yu,et al.  Proteomic analysis indicates the importance of TPM3 in esophageal squamous cell carcinoma invasion and metastasis , 2017, Molecular medicine reports.

[6]  Jia Wen Liang,et al.  Aberrant methylation of DACT1 and DACT2 are associated with tumor progression and poor prognosis in esophageal squamous cell carcinoma , 2017, Journal of Biomedical Science.

[7]  T. Xiao,et al.  iTRAQ-based quantitative analysis of cancer-derived secretory proteome reveals TPM2 as a potential diagnostic biomarker of colorectal cancer , 2016, Frontiers of Medicine.

[8]  J. Xiang,et al.  Role of cellular cytoskeleton in epithelial-mesenchymal transition process during cancer progression. , 2015, Biomedical reports.

[9]  Daniel P. Mulvihill,et al.  Tropomyosin – master regulator of actin filament function in the cytoskeleton , 2015, Journal of Cell Science.

[10]  M. Arnal,et al.  Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. , 2015 .

[11]  D. Dube,et al.  Expression of Tropomyosin 1 Gene Isoforms in Human Breast Cancer Cell Lines , 2015, International journal of breast cancer.

[12]  Jeffrey R. Moore,et al.  Direct observation of tropomyosin binding to actin filaments , 2015, Cytoskeleton.

[13]  Ping Zhang,et al.  Intratumoral polymorphonuclear granulocyte is associated with poor prognosis in squamous esophageal cancer by promoting epithelial-mesenchymal transition. , 2015, Future oncology.

[14]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[15]  Chunxi Wang,et al.  Clinical and tumor significance of tropomyosin-1 expression levels in renal cell carcinoma. , 2015, Oncology reports.

[16]  Christopher M. Fife,et al.  Movers and shakers: cell cytoskeleton in cancer metastasis , 2014, British journal of pharmacology.

[17]  P. Gunning,et al.  A systematic nomenclature for mammalian tropomyosin isoforms , 2014, Journal of Muscle Research and Cell Motility.

[18]  J. Ferlay,et al.  Global incidence of oesophageal cancer by histological subtype in 2012 , 2014, Gut.

[19]  G. Calin,et al.  Expression, Tissue Distribution and Function of miR-21 in Esophageal Squamous Cell Carcinoma , 2013, PloS one.

[20]  D. Speicher,et al.  Protein isoform-specific validation defines multiple chloride intracellular channel and tropomyosin isoforms as serological biomarkers of ovarian cancer. , 2013, Journal of proteomics.

[21]  Yuan-yuan Wang,et al.  miR-21 Down-Regulation Suppresses Cell Growth, Invasion and Induces Cell Apoptosis by Targeting FASL, TIMP3, and RECK Genes in Esophageal Carcinoma , 2013, Digestive Diseases and Sciences.

[22]  H. Baba,et al.  A review of the alterations in DNA methylation in esophageal squamous cell carcinoma , 2013, Surgery Today.

[23]  M. Zare,et al.  Downregulation of tropomyosin‐1 in squamous cell carcinoma of esophagus, the role of Ras signaling and methylation , 2012, Molecular carcinogenesis.

[24]  Sheung Tat Fan,et al.  Identification and Characterization of Tropomyosin 3 Associated with Granulin-Epithelin Precursor in Human Hepatocellular Carcinoma , 2012, PloS one.

[25]  Amir Reza Radmard,et al.  Five common cancers in Iran. , 2010, Archives of Iranian medicine.

[26]  Shadan Ali,et al.  Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. , 2010, American journal of translational research.

[27]  Kenneth K Wang,et al.  Screening, surveillance, and prevention for esophageal cancer. , 2009, Gastroenterology clinics of North America.

[28]  G. O'Neill,et al.  Tropomyosin-based regulation of the actin cytoskeleton in time and space. , 2008, Physiological reviews.

[29]  David E. Misek,et al.  Comparative Proteomics Analysis of Barrett Metaplasia and Esophageal Adenocarcinoma Using Two-dimensional Liquid Mass Mapping*S , 2007, Molecular & Cellular Proteomics.

[30]  Shuomin Zhu,et al.  MicroRNA-21 Targets the Tumor Suppressor Gene Tropomyosin 1 (TPM1)* , 2007, Journal of Biological Chemistry.

[31]  T. Junginger,et al.  Novel therapeutic targets in esophageal cancer: impact of chemokine receptor CXCR4. , 2007, Future oncology.

[32]  N. Iizuka,et al.  Expression of tropomyosin alpha 4 chain is increased in esophageal squamous cell carcinoma as evidenced by proteomic profiling by two‐dimensional electrophoresis and liquid chromatography‐mass spectrometry/mass spectrometry , 2007, Proteomics. Clinical applications.

[33]  G. O'Neill,et al.  Specialisation of the tropomyosin composition of actin filaments provides new potential targets for chemotherapy. , 2006, Current cancer drug targets.

[34]  Andrei V Bakin,et al.  Silencing of the Tropomyosin-1 gene by DNA methylation alters tumor suppressor function of TGF-β , 2005, Oncogene.

[35]  Nicole S. Bryce,et al.  Tissue-specific Tropomyosin Isoform Composition , 2005, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[36]  James L. Abbruzzese,et al.  Protein Expression Profiles in Pancreatic Adenocarcinoma Compared with Normal Pancreatic Tissue and Tissue Affected by Pancreatitis as Detected by Two-Dimensional Gel Electrophoresis and Mass Spectrometry , 2004, Cancer Research.

[37]  H. Kuwano,et al.  Genetic Alterations in Esophageal Cancer , 2004, Surgery Today.

[38]  M. Willingham,et al.  Loss of expression of tropomyosin-1, a novel class II tumor suppressor that induces anoikis, in primary breast tumors , 2003, Oncogene.

[39]  G. O'Neill,et al.  Functional analysis of the actin-binding protein, tropomyosin 1, in neuroblastoma , 2003, British Journal of Cancer.

[40]  S. Bharadwaj,et al.  Tropomyosin-1, a novel suppressor of cellular transformation is downregulated by promoter methylation in cancer cells. , 2002, Cancer letters.

[41]  M. Willingham,et al.  Suppression of the transformed phenotype of breast cancer by tropomyosin-1. , 2002, Experimental cell research.

[42]  C. Der,et al.  Opposing Roles of the Extracellular Signal-Regulated Kinase and p38 Mitogen-Activated Protein Kinase Cascades in Ras-Mediated Downregulation of Tropomyosin , 2002, Molecular and Cellular Biology.

[43]  D. Helfman,et al.  Cytoskeletal changes in cell transformation and tumorigenesis. , 2001, Current opinion in genetics & development.

[44]  A. Ben-Ze'ev,et al.  Cytoskeletal and adhesion proteins as tumor suppressors. , 1997, Current opinion in cell biology.

[45]  J. Lin,et al.  Tropomyosin isoforms in nonmuscle cells. , 1997, International review of cytology.

[46]  P. Kantoff,et al.  Two differentially expressed genes in normal human prostate tissue and in carcinoma. , 1996, Cancer research.

[47]  H. Kato,et al.  Expression of tropomyosin isoforms in benign and malignant human breast lesions. , 1996, British Journal of Cancer.

[48]  E Button,et al.  Actin, its associated proteins and metastasis. , 1995, Cell motility and the cytoskeleton.

[49]  D. Helfman,et al.  Functional properties of non-muscle tropomyosin isoforms. , 1994, Current opinion in cell biology.